Selected Grants
TBCRC 041 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by Mayo Clinic · 2019 - 2024Kastan Gray Foundation Project
ResearchResearcher · Awarded by Gray Foundation · 2017 - 2024TBCRC48 A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2023Postdoctoral Training in Genomic Medicine Research
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2017 - 2023TBCRC AURORA US:RETROSPECTIVE TISSUE COLLECTION
ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2017 - 2023A randomized phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs Paclitaxel in combination with Trastuzumab for stage I HER2-positive breast cancer (ATEMPT Trial)
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2014 - 2022A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with eitherLEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2016 - 2022Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer
ResearchCollaborator · Awarded by Department of Defense · 2019 - 2022Translational Breast Cancer Research Consortium 2020 Infrastructure - SGK
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2020 - 2022Translational Breast Cancer Research Consortium 2020 Infrastructure (BCRF)
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2020 - 2022A RANDOMIZED PHASE II STUDY OF PREOPERATIVE CISPLATIN VS PACLITAXEL IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER WITHOUT GERMLINE BRCA MUTATIONS: EVALUATING THE HOMOLOGOUS RECOMBINATION DEFICIENCY (HRB) BIOMARKER
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2014 - 2022Targeting Dormant Breast Cancer Micrometastases to Prevent Disease Relapse
ResearchCo Investigator · Awarded by American Cancer Society, Inc. · 2019 - 2022Translational Breast Cancer Research Consortium 2019 Infrastructure - SGK
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2019 - 2021Translational Breast Cancer Research Consortium 2019 Infrastructure (BCRF)
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2019 - 2021Deep learning for prognostication in breast cancer
ResearchCo Investigator · Awarded by North Carolina Biotechnology Center · 2018 - 2021Translational Breast Cancer Research Consortium 2018 Infrastructure - SGK
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2020Translational Breast Cancer Research Consortium 2018 Infrastructure (BCRF)
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2020Can contrast dynamics in breast MRI predict genomic intra-tumor heterogeneity
ResearchInvestigator · Awarded by Bracco Diagnostics, Inc. · 2016 - 2020Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells
ResearchCo Investigator · Awarded by Department of Defense · 2017 - 2020A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.
ResearchPrincipal Investigator · Awarded by Innocrin Pharmaceutical, Inc. · 2016 - 2019Translational Breast Cancer Research Consortium-2017 Komen Foundation SGK
ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2019RANDOMIZED PHASE II TRIAL OF NEOADJUVANT CISPLATIN VS. DOXORUBICIN/CYCLOPHOSPHAMIDE (¿AC¿) IN WOMEN WITH NEWLY DIAGNOSED BREAST CANCER AND GERMLINE BRCA MUTATIONS
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2015 - 2019TBCRC 031 INFORM (Beth Israel)
Clinical TrialPrincipal Investigator · Awarded by Beth Israel Deaconess Medical Center · 2015 - 2019A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2017 - 2018A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (CDX011-04)
ResearchPrincipal Investigator · Awarded by Celldex Therapeutics, Inc. · 2014 - 2018A PHASE II RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF LETROZOLE WITH OR WITHOUT BYL719 OR BUPARLISIB, FOR THE NEOADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE BREAST CANCER
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2013 - 2017Commericialization of a computational imaging-based biomarker for prognostication in breast cancer
ResearchClinical Consultant · Awarded by North Carolina Biotechnology Center · 2016 - 2017Targeting nuclear FGF receptor to improve chemotherapy response in triple-negative breast cancer
ResearchInvestigator · Awarded by Department of Defense · 2013 - 2016Clinical Oncology Research Career Development Program
ResearchMentor · Awarded by National Institutes of Health · 2009 - 2015Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2010 - 2014Programs in Clinical Effectiveness of Cancer Pharmacogenomics
ResearchInvestigator · Awarded by National Institutes of Health · 2009 - 2012Markers of short term breast cancer risk in FNA
ResearchCo Investigator · Awarded by National Institutes of Health · 1995 - 2008Phase II trial of Cetuximab & Carboplatin in Basal-like Breast Cancer
Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 1995 - 2008Carolina and Georgia Genetics Network Center
ResearchCollaborator · Awarded by National Institutes of Health · 1998 - 2008Phase II Trial of Estradiol Therapy for Advanced Breast Cancer
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2003 - 2005Carolina and Georgia Genetics Network Center
ResearchCollaborator · Awarded by National Institutes of Health · 1998 - 2004External Relationships
- Veracyte
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.